Radiation inactivation analysis of microsomal UDP-glucuronosyltransferases catalysing mono- and diglucuronide formation of 3,6-dihydroxybenzo(a) pyrene and 3,6-dihydroxychryseneGSCHAIDMEIER, H; BOCK, K. W.Biochemical pharmacology. 1994, Vol 48, Num 8, pp 1545-1549, issn 0006-2952Article

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantationWASSMANN, B; SCHEURING, U; OTTMANN, O. G et al.Bone marrow transplantation (Basingstoke). 2003, Vol 31, Num 7, pp 611-614, issn 0268-3369, 4 p.Article

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-mediated membrane translocation of c-Src protein kinase in liver WB-F344 cellsKÖHLE, C; GSCHAIDMEIER, H; LAUTH, D et al.Archives of toxicology. 1999, Vol 73, Num 3, pp 152-158, issn 0340-5761Article

A randomized multicenter open label phase ii study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph⁺/BCR-ABL⁺) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)WASSMANN, B; GÖKBUGET, N; SCHEURING, U. J et al.Annals of hematology (Print). 2003, Vol 82, Num 11, pp 716-720, issn 0939-5555, 5 p.Article

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-CMÜLLER, M. C; GATTERMANN, N; KRAUSE, S. W et al.Leukemia. 2003, Vol 17, Num 12, pp 2392-2400, issn 0887-6924, 9 p.Article

Growth modulation of hepatocytes and rat liver epithelial cells (WB-F344) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)MÜNZEL, P; BOCK-HENNIG, B; SCHIEBACK, S et al.Carcinogenesis (New York. Print). 1996, Vol 17, Num 2, pp 197-202, issn 0143-3334Article

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparationsSCHLEYER, E; PURSCHE, S; BERGEMANN, T et al.Journal of chromatography. B. 2004, Vol 799, Num 1, pp 23-36, issn 1570-0232, 14 p.Article

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ALL) during imatinib treatment : Spotlight on imatinib as a model for signal transduction inhibitorsSCHEURING, U. J; PFEIFER, H; WASSMANN, B et al.Leukemia. 2003, Vol 17, Num 9, pp 1700-1706, issn 0887-6924, 7 p.Article

Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glcuronosyltransferase (UGT1A1)BOCK, K. W; GSCHAIDMEIER, H; SEIDEL, A et al.Molecular pharmacology. 1992, Vol 42, Num 4, pp 613-618, issn 0026-895XArticle

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)WASSMANN, B; PFEIFER, H; SCHEURING, U et al.Leukemia. 2002, Vol 16, Num 12, pp 2358-2365, issn 0887-6924, 8 p.Article

Density-dependent growth of normal and nodular hepatocytesBOCK, K. W; GSCHAIDMEIER, H; BOCK-HENNIG, B. S et al.Toxicology (Amsterdam). 2000, Vol 144, Num 1-3, pp 51-56, issn 0300-483XArticle

Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferasesBOCK, K. W; FORSTER, A; GSCHAIDMEIER, H et al.Biochemical pharmacology. 1993, Vol 45, Num 9, pp 1809-1814, issn 0006-2952Article

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon αMERX, K; MÜLLER, M. C; HEHLMANN, R et al.Leukemia. 2002, Vol 16, Num 9, pp 1579-1583, issn 0887-6924Article

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bar/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) : Spotlight on signal transduction inhibitors: Basic aspects and therapeutics implicationsFISCHER, T; REIFENRATH, C; HEHLMANN, R et al.Leukemia. 2002, Vol 16, Num 7, pp 1220-1228, issn 0887-6924Article

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantationWASSMANN, B; KLEIN, S. A; SCHEURING, U et al.Bone marrow transplantation (Basingstoke). 2001, Vol 28, Num 7, pp 721-724, issn 0268-3369Article

Mono- and diglucuronide formation from benzo[a]pyrene and chrysene diphenols by AHH-1 cell-expressed UDP-glucuronosyltransferase UGT1A7BOCK, K. W; RASCHKO, F. T; GSCHAIDMEIER, H et al.Biochemical pharmacology. 1999, Vol 57, Num 6, pp 653-656, issn 0006-2952Article

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-CKINDLER, T; BREITENBUECHER, F; KASPER, S et al.Leukemia. 2003, Vol 17, Num 6, pp 999-1009, issn 0887-6924, 11 p.Article

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-α (IFN-α) in philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL)WASSMANN, B; SCHEURING, U; PFEIFER, H et al.Leukemia. 2003, Vol 17, Num 10, pp 1919-1924, issn 0887-6924, 6 p.Article

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitorsPASCHKA, P; MÜLLER, M. C; GSCHAIDMEIER, H et al.Leukemia. 2003, Vol 17, Num 9, pp 1687-1694, issn 0887-6924, 8 p.Article

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyHOCHHAUS, A; KREIL, S; GSCHAIDMEIER, H et al.Leukemia. 2002, Vol 16, Num 11, pp 2190-2196, issn 0887-6924Article

Formation of mono- and diglucuronides and other glycosides of benzo(a)pyrene-3,6-quinol by V79 cell-expressed human phenol UDP-glucuronosyltransferases of the UGT1 gene complexGSCHAIDMEIER, H; SEIDEL, A; BURCHELL, B et al.Biochemical pharmacology. 1995, Vol 49, Num 11, pp 1601-1606, issn 0006-2952Article